Page last updated: 2024-09-02

fingolimod hydrochloride and ursodeoxycholic acid

fingolimod hydrochloride has been researched along with ursodeoxycholic acid in 2 studies

Compound Research Comparison

Studies (fingolimod hydrochloride)	Trials (fingolimod hydrochloride)	Recent Studies (post-2010) (fingolimod hydrochloride)	Studies (ursodeoxycholic acid)	Trials (ursodeoxycholic acid)	Recent Studies (post-2010) (ursodeoxycholic acid)
2,771	157	2,062	4,592	626	1,561

Protein Interaction Comparison

Protein	Taxonomy	ursodeoxycholic acid (IC50)
Bile salt export pump	Homo sapiens (human)	10
Sodium/bile acid cotransporter	Homo sapiens (human)	3.6
M1-family alanyl aminopeptidase	Plasmodium falciparum 3D7	2.6

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adinolfi, LE; Alfieri, G; Dalla Mora, L; Lus, G; Marrone, A; Rainone, I; Rinaldi, L; Signoriello, E	1
Ab Rahim, S; Abdul Hamid Hasani, N; Hanafi, NI; Md Noor, J; Mohamed, AS; Sheikh Abdul Kadir, SH; Siran, R	1

Other Studies

2 other study(ies) available for fingolimod hydrochloride and ursodeoxycholic acid

Article	Year
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. Le infezioni in medicina, 2014, Volume: 22, Issue:4 Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment	2014
Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein. Cell biochemistry and function, 2017, Volume: 35, Issue:7 Topics: Animals; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Cobalt; Fingolimod Hydrochloride; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Myocytes, Cardiac; Pertussis Toxin; Protective Agents; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Tumor Suppressor Protein p53; Ursodeoxycholic Acid	2017

Article

Year

Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.

Le infezioni in medicina, 2014, Volume: 22, Issue:4

Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment

2014

Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein.

Cell biochemistry and function, 2017, Volume: 35, Issue:7

Topics: Animals; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Cobalt; Fingolimod Hydrochloride; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Myocytes, Cardiac; Pertussis Toxin; Protective Agents; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Tumor Suppressor Protein p53; Ursodeoxycholic Acid

2017